Makker Jasbir, Mantri Nikhitha, Patel Harish K, Abbas Hafsa, Baiomi Ahmed, Sun Haozhe, Choi Yongsub, Chilimuri Sridhar, Nayudu Suresh Kumar
Division of Gastroenterology, BronxCare Hospital Center, Clinical Affiliate of Mt Sinai Health Systems and Academic Affiliate of Icahn School of Medicine, Bronx, NY, 10457, USA.
Department of Medicine, BronxCare Hospital Center, Clinical Affiliate of Mt Sinai Health Systems and Academic Affiliate of Icahn School of Medicine, Bronx, NY, 10457, USA.
Clin Exp Gastroenterol. 2021 Oct 8;14:405-411. doi: 10.2147/CEG.S318149. eCollection 2021.
Patients requiring hospitalization to critical care units are at a higher risk for gastrointestinal (GI) bleeding. Although severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is predominantly a pulmonary disease, other serious manifestations including thromboembolic phenomenon are reported. Acute respiratory distress syndrome (ARDS) requiring mechanical ventilation, use of steroids and anticoagulation are all known to increase the risk of GI bleeding significantly.
To study the incidence of GI bleeding and its impact on mortality in patients admitted with SARS-CoV-2.
We retrospectively reviewed all patients admitted with SARS-CoV-2 from February 1, 2020 to April 15, 2020. We collected data including demographics, comorbid conditions, laboratory parameters, steroid and anticoagulant use. Coffee ground emesis, hematemesis, melena and hematochezia were defined as GI bleeding. All-cause mortality was reviewed for all patients included in the study. The relationship between GI bleeding and mortality was studied using logistic regression.
We had a total of 1206 patients hospitalized with SARS-CoV-2 infection with an all-cause mortality of 34% (n = 411). The overall incidence of GI bleeding was 3.1% (n = 37) with no significant difference between the patients who survived versus died during hospitalization (1.3% vs 1.5%, p = 0.77). Logistic regression analysis did not identify GI bleeding as an independent predictor of mortality. Therapeutic doses of anticoagulation were administered in 13.3% (n = 161) of patients, of which 6.8% (n = 11) developed GI bleeding. Patients were more likely to develop GI bleeding with use of therapeutic doses of anticoagulation (29.7% vs 12.8%, p = 0.003), steroids (37.8% vs 18.5%, p = 0.003) and mechanical ventilation (48.6% vs 30.4%, p = 0.018).
Patients hospitalized with SARS-CoV-2 infection are at risk of gastrointestinal bleeding. Therapeutic doses of anticoagulation, mechanical ventilation and steroid use are significant risk factors for GI bleeding. However, GI bleeding did not significantly alter the mortality rates in SARS-CoV-2-infected patients.
需要住院到重症监护病房的患者发生胃肠道(GI)出血的风险更高。虽然严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染主要是一种肺部疾病,但也有其他严重表现的报道,包括血栓栓塞现象。需要机械通气、使用类固醇和抗凝治疗的急性呼吸窘迫综合征(ARDS)都已知会显著增加胃肠道出血的风险。
研究SARS-CoV-2感染患者胃肠道出血的发生率及其对死亡率的影响。
我们回顾性分析了2020年2月1日至2020年4月15日期间所有SARS-CoV-2感染患者。我们收集了包括人口统计学、合并症、实验室参数、类固醇和抗凝剂使用情况等数据。咖啡渣样呕吐物、呕血、黑便和便血被定义为胃肠道出血。对研究中纳入的所有患者进行全因死亡率评估。使用逻辑回归分析研究胃肠道出血与死亡率之间的关系。
我们共有1206例SARS-CoV-2感染住院患者,全因死亡率为34%(n = 411)。胃肠道出血的总体发生率为3.1%(n = 37),住院期间存活患者与死亡患者之间无显著差异(1.3%对1.5%,p = 0.77)。逻辑回归分析未将胃肠道出血确定为死亡率的独立预测因素。13.3%(n = 161)的患者接受了治疗剂量的抗凝治疗,其中6.8%(n = 11)发生了胃肠道出血。使用治疗剂量的抗凝剂(29.7%对12.8%,p = 0.003)、类固醇(37.8%对18.5%,p = 0.003)和机械通气(48.6%对30.4%,p = 0.018)的患者更有可能发生胃肠道出血。
SARS-CoV-2感染住院患者有胃肠道出血的风险。治疗剂量的抗凝治疗、机械通气和类固醇使用是胃肠道出血的重要危险因素。然而,胃肠道出血并未显著改变SARS-CoV-2感染患者的死亡率。